SPG11 Research Update – First Results Are Promising

The research into a potential treatment for SPG11, conducted by Paris Brain Institute, began in April 2025 and is progressing according to plan. This is preclinical research in mouse models and is funded by Euro-HSP and Life4HSP.

The study focuses on the efficacy and safety of the drug venglustat. Initial evaluations in mice show that the drug is well tolerated and suggest a possible improvement in both motor and cognitive functions. These results are cautiously encouraging and align with findings from previous studies.

In the coming period, the focus will be on continuing the research and collecting additional data. These data are essential to confirm the results and to assess whether further steps toward additional studies are possible and responsible.

We will continue to closely monitor progress and keep you informed of new developments. Thanks to the support of donors and partners, this important research into SPG11 can continue.